Others have previously explored whether miRNA-221 levels in circulating blood can be used as a biomarker for the diagnosis and prognosis of NKTCL [6], and shown that miRNA-146a downregulates the activity of NF-KB by regulating the target molecule TRAF6, which is a tumor suppressor gene in NKTCL and is related to patient prognosis [7]. The gene discussed is NFKB1; the disease is extranodal nasal NK/T cell lymphoma.